CN114222580A - 一种预防和/或治疗卵巢癌的多肽药物及其用途 - Google Patents

一种预防和/或治疗卵巢癌的多肽药物及其用途 Download PDF

Info

Publication number
CN114222580A
CN114222580A CN202080057173.0A CN202080057173A CN114222580A CN 114222580 A CN114222580 A CN 114222580A CN 202080057173 A CN202080057173 A CN 202080057173A CN 114222580 A CN114222580 A CN 114222580A
Authority
CN
China
Prior art keywords
gly
leu
asp
arg
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080057173.0A
Other languages
English (en)
Other versions
CN114222580B (zh
Inventor
杨宝峰
杨新春
赵金龙
刘宇
杜伟杰
王准
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Teng Pai Pharmaceutical Co ltd
Original Assignee
Zhuhai Teng Pai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Teng Pai Pharmaceutical Co ltd filed Critical Zhuhai Teng Pai Pharmaceutical Co ltd
Publication of CN114222580A publication Critical patent/CN114222580A/zh
Application granted granted Critical
Publication of CN114222580B publication Critical patent/CN114222580B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供一种多肽、含有多肽的组合物及其在制备用于预防和/或治疗卵巢癌的药物中的用途，所述多肽的氨基酸序列为：Arg‑Gly‑Asp‑Arg‑Gly‑Asp‑Met‑His‑Ser‑His‑Arg‑Asp‑Phe‑Gln‑Pro‑Val‑Leu‑His‑Leu‑Val‑Ala‑Leu‑Asn‑Ser‑Pro‑Leu‑Ser‑Gly‑Gly‑Met。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202080057173.0A 2020-02-13 2020-02-17 一种预防和/或治疗卵巢癌的多肽药物及其用途 Active CN114222580B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010089780.7A CN113244371A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗卵巢癌的多肽药物及其用途
CN2020100897807 2020-02-13
PCT/CN2020/075601 WO2021159547A1 (zh) 2020-02-13 2020-02-17 一种预防和/或治疗卵巢癌的多肽药物及其用途

Publications (2)

Publication Number Publication Date
CN114222580A true CN114222580A (zh) 2022-03-22
CN114222580B CN114222580B (zh) 2022-12-06

Family

ID=77219778

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010089780.7A Pending CN113244371A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗卵巢癌的多肽药物及其用途
CN202080057173.0A Active CN114222580B (zh) 2020-02-13 2020-02-17 一种预防和/或治疗卵巢癌的多肽药物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010089780.7A Pending CN113244371A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗卵巢癌的多肽药物及其用途

Country Status (2)

Country Link
CN (2) CN113244371A (zh)
WO (1) WO2021159547A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1463978A (zh) * 2002-06-05 2003-12-31 中国人民解放军军事医学科学院野战输血研究所 一种卵巢癌相关基因及其编码的蛋白质
CN104530199A (zh) * 2014-11-18 2015-04-22 哈尔滨医科大学 一种抗肿瘤多肽及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107245103A (zh) * 2016-12-30 2017-10-13 广西壮族自治区药用植物园 抗肿瘤重组蛋白ifti及其编码基因与应用
CN107778362B (zh) * 2017-11-22 2021-03-30 哈尔滨医科大学 一种用于抑制口腔鳞状细胞癌迁移和侵袭能力的多肽及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1463978A (zh) * 2002-06-05 2003-12-31 中国人民解放军军事医学科学院野战输血研究所 一种卵巢癌相关基因及其编码的蛋白质
CN104530199A (zh) * 2014-11-18 2015-04-22 哈尔滨医科大学 一种抗肿瘤多肽及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONG X等: "A LC-MS/MS method to monitor the concentration of HYD-PEP06, a RGD-modified Endostar mimetic peptide in rat blood", 《JOURNAL OF CHROMATOGRAPHY B》 *
赖军明等: "重组人血管内皮抑制素在女性恶性肿瘤治疗中的临床应用", 《实用临床医学》 *

Also Published As

Publication number Publication date
CN113244371A (zh) 2021-08-13
CN114222580B (zh) 2022-12-06
WO2021159547A1 (zh) 2021-08-19

Similar Documents

Publication Publication Date Title
CN107708702A (zh) 磷脂醚类似物作为靶向癌症的药物载体
EP3429614B1 (en) Method of treating triple negative breast cancer
US20210254069A1 (en) Combination therapies comprising c/ebp alpha sarna
WO2021180111A1 (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
CN113577070B (zh) 一种治疗急性髓系白血病的联合用药物组合物及其应用
CA2912830A1 (en) Specific cancer treatment regimens with ganetespib
CN114222580B (zh) 一种预防和/或治疗卵巢癌的多肽药物及其用途
WO2014180304A1 (zh) J1-001化合物作为抗癌药物的用途
JP5579699B2 (ja) 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物
WO2017177515A1 (zh) 4-羟基水杨酰苯胺在制备抗骨髓瘤、淋巴瘤药物中的应用
CN108853114B (zh) 硝呋莫司在制备治疗癌症衍生的脑转移瘤的药物中的应用
CN114222753B (zh) 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN115190800A (zh) 一种brd4抑制剂的用途
WO2017045595A1 (zh) 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
CN111514298B (zh) 质子泵抑制剂与pd-1轴结合拮抗剂的组合及其用途
RU2693463C2 (ru) Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта
CN110856718A (zh) 苯并异硒唑衍生物与铂类药物联合用于制备治疗肿瘤药物与术后肿瘤复发药物中的应用
CN111803482B (zh) 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物
CN114948951B (zh) Fk506或其可药用衍生物和铁死亡诱导剂或其可药用衍生物联合在制备治疗癌症的药物中的用途
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
US20240207304A1 (en) Combination Therapies Comprising C/EBP Alpha saRNA
CN115227690A (zh) 土木香内酯在双表达型b细胞淋巴瘤中的应用
KR101320485B1 (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 항암제 조성물
CN118304412A (zh) 一种特异性阻断acvr1c与grem1结合的多肽及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Yang Xinchun

Inventor after: Zhao Jinlong

Inventor after: Yang Baofeng

Inventor after: Liu Yu

Inventor after: Du Weijie

Inventor after: Wang Zhun

Inventor before: Yang Baofeng

Inventor before: Yang Xinchun

Inventor before: Zhao Jinlong

Inventor before: Liu Yu

Inventor before: Du Weijie

Inventor before: Wang Zhun

GR01 Patent grant
GR01 Patent grant